Babiloni, ClaudioGüntekin, Bahar2023-07-142023-07-142023Babiloni, C. ve Güntekin, B. (2023). EEG, ERPs, and EROs in patients with cognitive deficits due to progressive neurodegenerative diseases: The dark side of the precision medicine. International Journal of Psychophysiology, 190, 56-59. https://doi.org/10.1016/j.ijpsycho.2023.06.0050167-87601872-7697https://doi.org/10.1016/j.ijpsycho.2023.06.005https://hdl.handle.net/20.500.12511/11196Many millions of patients worldwide live with age-related progressive neurodegenerative diseases such as Alzheimer's, Parkinson's, Lewy body, and others belonging to severe cognitive deficits and disabilities in the activities of daily living (i.e., dementia) until death after a disease course of 10–15 years (Lemstra et al., 2017; Teipel et al., 2022). Indeed, no effective disease-blocking therapy is available to date. These diseases are caused by insufficient homeostasis of potentially neurotoxic proteins (e.g., amyloid, phospho tau, alpha-synuclein, TDP-43, light neurofibrillary chains) that progressively accumulate in the brain, affecting synaptic transmission and the generation and conduction of action potentials until neural loss (Lemstra et al., 2017; Jack Jr et al., 2018; Scott et al., 2022; Teipel et al., 2022).eninfo:eu-repo/semantics/embargoedAccessPrecision MedicineNeurodegenerative DiseasesCognitive DeficitsEROsEEGERPsEditorial190565910.1016/j.ijpsycho.2023.06.005Q20010303581000012-s2.0-8516322095737302661Q2